Immuneering

Immuneering Corporation's stock surged 55% after Phase 2a trial data for IMM-1-104 showed promising results in pancreatic cancer treatment, with a 43% ORR and 86% DCR when combined with gemcitabine/nab-paclitaxel. The therapy also showed tumor shrinkage with modified FOLFIRINOX and has FDA Fast Track designation, indicating potential for faster approval.

Immuneering's IMM-1-104 shows high efficacy in Phase 2a trials for pancreatic cancer, with a 43% ORR and 86% DCR when combined with gemcitabine/nab-paclitaxel, and tumor shrinkage with modified FOLFIRINOX. Monotherapy data also promising. Plans to expand trials in 2025 to explore IMM-1-104's potential across various cancers.

IMM-1-104 shows promising results in pancreatic cancer trials, with a 43% ORR and 86% DCR in combination with mGnP, and target lesion shrinkage in all evaluable patients with mFFX. Monotherapy also demonstrated activity, with a 67% reduction in one case. Plans for pivotal trials and additional combination arms are underway, supported by a favorable tolerability profile.

Immuneering Corporation's stock surged 133.90% to $5.52 after positive Phase 2a trial data for IMM-1-104, a novel MEK inhibitor for pancreatic cancer, showing a 43% ORR and 86% DCR. The therapy's potential in treating RAS-mutated tumors and its differentiated safety profile have drawn investor optimism, positioning Immuneering as a potential leader in oncology.

Immuneering Corporation reported positive Phase 2a trial data for IMM-1-104 in pancreatic cancer, showing promising response rates and tolerability. The trial is expanding to include more combination arms. IMM-1-104, designed for RAS-mutated tumors, showed efficacy in first and second-line treatments, with FDA Fast Track and orphan drug designations.

Immuneering (IMRX) reported positive Phase 2a trial results for IMM-1-104 in pancreatic cancer, showing a 43% overall response rate and 86% disease control rate. Plans to expand the trial with three additional combination arms were announced.

Immuneering reports positive Phase 2a trial data for IMM-1-104 in pancreatic cancer, showing high response and disease control rates. Plans to expand trials with new combination arms. IMM-1-104 demonstrates a favorable tolerability profile, aiming to improve upon existing MEK inhibitors. Further data expected in 2Q’25.

IMM-1-104 shows promising results in pancreatic cancer trials, with a 43% ORR and 86% DCR in combination with mGnP, and target lesion shrinkage in all evaluable patients with mFFX. Monotherapy also demonstrates activity. Plans for pivotal trials and additional combination arms are underway, with further data expected in 2Q’25.

Immuneering Corporation reports positive Phase 2a trial data for IMM-1-104 in pancreatic cancer, showing a 43% ORR and 86% DCR with modified gemcitabine/nab-paclitaxel, and target lesion shrinkage in all evaluable patients with modified FOLFIRINOX. IMM-1-104 monotherapy also shows promise. Plans for pivotal trials and additional combination arms are underway, with further data expected in 2Q’25.

Immuneering Corporation's stock surged 55% after positive Phase 2a trial results for IMM-1-104 in pancreatic cancer, showing improved response and disease control rates. Plans to expand the study and FDA Fast Track designation for pancreatic cancer and melanoma treatments were announced, with further data expected in 2025.